Skip to main
DMRA

Galecto Inc (DMRA) Stock Forecast & Price Target

Galecto Inc (DMRA) Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 25%
Buy 75%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Damora Therapeutics is a relatively new biotechnology company with a strong focus on addressing a crucial medical need for patients with hematologic disorders, specifically those with mutant calreticulin-driven myeloproliferative neoplasms. With a diverse pipeline and goal of bringing forward convenient and effective therapies for these conditions, Damora has the potential for significant growth and success in the biotech industry. The involvement of industry experts in their treatments further adds to the credibility and potential success of the company.

Bears say

Damora Therapeutics is targeting a specific subset of patients with hematologic disorders, and while their therapies show potential, there is a risk that their competitors, such as INCA033989, may capture the majority of the market with a head start and established efficacy data. Furthermore, Damora's valuation may seem low given their cash reserves and their expected runway into 2029, but this could be due to uncertainties around their future success and the potential for competitors to outperform their therapies. Overall, there is a significant level of risk associated with investing in Damora Therapeutics at this stage, with a negative outlook for their stock.

Galecto Inc (DMRA) has been analyzed by 4 analysts, with a consensus rating of Buy. 25% of analysts recommend a Strong Buy, 75% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Galecto Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Galecto Inc (DMRA) Forecast

Analysts have given Galecto Inc (DMRA) a Buy based on their latest research and market trends.

According to 4 analysts, Galecto Inc (DMRA) has a Buy consensus rating as of Jun 22, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $41.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $41.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Galecto Inc (DMRA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.